SCHEMBL7664699

SCHEMBL7664699

CC(=O)On1c(=O)c(-c2cn(Cc3cccc(CN)c3)c3ccc(Br)cc23)nc2cc3ccccc3cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDE4B Q07343 3/20 0.35
PDE4D Q08499 3/20 0.35
PLA2G2A P14555 1/20 0.34
LMNA P02545 2/20 0.34
PDE4A P27815 2/20 0.34
PDE4C Q08493 2/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 1/20 0.34
EGFR P00533 1/20 0.34
MET P08581 1/20 0.34
USP2 O75604 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7657926 0.92 USP2 (0.41) POLBALDH1A1SMN1; SMN2PDE4BPDE4D
SCHEMBL7663837 0.88 TP53 (0.44) POLBALDH1A1SMN1; SMN2FNTAFNTB
SCHEMBL7654522 0.87 ALDH1A1 (0.42) POLBALDH1A1SMN1; SMN2PDE4BPDE4D
SCHEMBL7662061 0.83 POLB (0.38) POLBPDE4BPDE4DLMNAPDE4A
SCHEMBL7666306 0.83 USP2 (0.39) POLBALDH1A1PDE4BPDE4DLMNA
SCHEMBL7660922 0.82 PDE4A (0.37) POLBPDE4BPDE4DLMNAPDE4A
SCHEMBL7652540 0.82 PDE4A (0.37) POLBPDE4BPDE4DLMNAPDE4A
Acetic Acid SCHEMBL7664692 0.82 MEN1 (0.38) PDE4BPDE4DPDE4APDE4CMEN1
SCHEMBL8516249 0.81 F2RL3 (0.40) POLBPDE4BPDE4DLMNAPDE4A
SCHEMBL7662878 0.80 ACKR3 (0.36) ALDH1A1SMN1; SMN2PDE4BPDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US claimed
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US disclosed